Lantern Pharma (LTRN) Competitors $3.85 -0.05 (-1.28%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN vs. IPHA, FULC, OCGN, CYBN, IKT, TLSA, LRMR, MOLN, PBYI, and GLSIShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Innate Pharma (IPHA), Fulcrum Therapeutics (FULC), Ocugen (OCGN), Cybin (CYBN), Inhibikase Therapeutics (IKT), Tiziana Life Sciences (TLSA), Larimar Therapeutics (LRMR), Molecular Partners (MOLN), Puma Biotechnology (PBYI), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. Innate Pharma Fulcrum Therapeutics Ocugen Cybin Inhibikase Therapeutics Tiziana Life Sciences Larimar Therapeutics Molecular Partners Puma Biotechnology Greenwich LifeSciences Innate Pharma (NASDAQ:IPHA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Does the media prefer IPHA or LTRN? In the previous week, Innate Pharma had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Innate Pharma and 0 mentions for Lantern Pharma. Innate Pharma's average media sentiment score of 0.37 beat Lantern Pharma's score of 0.00 indicating that Innate Pharma is being referred to more favorably in the media. Company Overall Sentiment Innate Pharma Neutral Lantern Pharma Neutral Does the MarketBeat Community favor IPHA or LTRN? Innate Pharma received 34 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 58.97% of users gave Innate Pharma an outperform vote. CompanyUnderperformOutperformInnate PharmaOutperform Votes4658.97% Underperform Votes3241.03% Lantern PharmaOutperform Votes1275.00% Underperform Votes425.00% Which has higher valuation and earnings, IPHA or LTRN? Innate Pharma has higher revenue and earnings than Lantern Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$24.85M6.63-$8.19MN/AN/ALantern PharmaN/AN/A-$15.96M-$1.78-2.19 Which has more risk and volatility, IPHA or LTRN? Innate Pharma has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Do institutionals & insiders have more ownership in IPHA or LTRN? 0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 7.3% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is IPHA or LTRN more profitable? Innate Pharma's return on equity of 0.00% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Lantern Pharma N/A -56.91%-51.17% Do analysts prefer IPHA or LTRN? Innate Pharma currently has a consensus price target of $11.50, suggesting a potential upside of 485.24%. Given Innate Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Innate Pharma is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Lantern Pharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryInnate Pharma beats Lantern Pharma on 12 of the 15 factors compared between the two stocks. Remove Ads Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.12M$7.01B$5.69B$8.29BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-2.197.2324.6119.30Price / SalesN/A231.43396.0094.72Price / CashN/A65.6738.1634.64Price / Book1.046.647.074.46Net Income-$15.96M$142.13M$3.20B$247.07M7 Day Performance4.13%3.04%1.61%3.17%1 Month Performance-1.64%2.80%5.93%-2.74%1 Year Performance-60.64%-4.32%15.12%4.67% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma0.1589 of 5 stars$3.85-1.3%N/A-63.4%$41.52MN/A-2.1620Upcoming EarningsIPHAInnate Pharma2.3095 of 5 stars$2.02+0.8%$11.50+470.7%-18.4%$168.92M$24.85M0.00220Upcoming EarningsNews CoverageFULCFulcrum Therapeutics1.885 of 5 stars$3.12flat$8.63+176.4%-66.8%$168.41M$80M-10.06100Positive NewsOCGNOcugen0.9313 of 5 stars$0.57+6.1%$6.33+1,011.1%-61.1%$166.45M$4.06M-3.1780Gap UpCYBNCybin2.7879 of 5 stars$7.65+1.1%$86.00+1,024.2%N/A$164.30MN/A-1.7550IKTInhibikase Therapeutics0.9792 of 5 stars$2.36+4.9%$6.50+175.4%+6.3%$163.69M$260,000.00-0.886TLSATiziana Life Sciences0.5505 of 5 stars$1.55-1.3%N/A+132.3%$163.36MN/A0.008Gap DownLRMRLarimar Therapeutics2.5085 of 5 stars$2.55-1.5%$20.13+689.2%-71.8%$162.71MN/A-2.2230Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageMOLNMolecular Partners1.5542 of 5 stars$4.03-7.0%$12.00+198.1%-2.5%$162.46M$4.97M-1.87180PBYIPuma Biotechnology4.0192 of 5 stars$3.24-2.4%$7.00+116.0%-34.9%$160.74M$230.47M6.75200Positive NewsGLSIGreenwich LifeSciences1.6316 of 5 stars$12.21+1.8%$38.00+211.2%-42.7%$160.50MN/A-15.263 Remove Ads Related Companies and Tools Related Companies IPHA Alternatives FULC Alternatives OCGN Alternatives CYBN Alternatives IKT Alternatives TLSA Alternatives LRMR Alternatives MOLN Alternatives PBYI Alternatives GLSI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LTRN) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LTRN Stock Free LTRN Stock Alerts